Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations

Apollomics Inc. announced that the FDA has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of NSCLC with MET genomic tumor aberrations.